clinical trial · NCT05459571
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Kite, A Gilead Company·phase2·completed·n = 35
Relapsed or Refractory Large B-cell LymphomaAxicabtagene CiloleucelCyclophosphamideFludarabineDexamethasone
brief summary
The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
started
Aug 9, 2022
primary completion
Nov 24, 2025
completion
Nov 24, 2025
last updated
Feb 2, 2026
detailed description
Participants who complete at minimum 24 months follow up will be transitioned to a separate long-term follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.
official title
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol